Candel Therapeutics’ (CADL) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Candel Therapeutics (NASDAQ:CADL) in a report published on Wednesday,Benzinga reports. They currently have a $19.00 price objective on the stock.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group started coverage on shares of Candel Therapeutics in a report on Wednesday, February 19th. They set a “buy” rating and a $20.00 price target for the company. Bank of America initiated coverage on shares of Candel Therapeutics in a report on Friday, February 7th. They set a “buy” rating and a $15.00 price objective for the company. Finally, Citigroup began coverage on Candel Therapeutics in a report on Thursday, February 20th. They issued a “buy” rating and a $25.00 target price on the stock.

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $8.47 on Wednesday. Candel Therapeutics has a 52-week low of $1.34 and a 52-week high of $14.60. The stock has a fifty day moving average price of $8.37 and a two-hundred day moving average price of $6.72. The firm has a market capitalization of $275.07 million, a P/E ratio of -4.90 and a beta of -1.25.

Insider Buying and Selling

In other news, CTO Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock in a transaction on Friday, November 29th. The stock was sold at an average price of $4.56, for a total value of $92,987.52. Following the completion of the sale, the chief technology officer now directly owns 125,657 shares of the company’s stock, valued at approximately $572,995.92. This trade represents a 13.96 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Garrett Nichols sold 13,935 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $4.56, for a total value of $63,543.60. Following the sale, the insider now owns 100,547 shares of the company’s stock, valued at approximately $458,494.32. The trade was a 12.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 75,856 shares of company stock worth $470,044 in the last 90 days. Corporate insiders own 41.60% of the company’s stock.

Institutional Trading of Candel Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC boosted its stake in shares of Candel Therapeutics by 86.6% in the 4th quarter. Squarepoint Ops LLC now owns 19,311 shares of the company’s stock valued at $168,000 after purchasing an additional 8,962 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in Candel Therapeutics by 3.0% in the fourth quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company’s stock valued at $592,000 after buying an additional 2,009 shares during the period. Maven Securities LTD acquired a new position in Candel Therapeutics in the fourth quarter valued at approximately $449,000. Millennium Management LLC boosted its stake in Candel Therapeutics by 130.6% in the fourth quarter. Millennium Management LLC now owns 31,626 shares of the company’s stock valued at $275,000 after acquiring an additional 17,914 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Candel Therapeutics by 12.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company’s stock worth $106,000 after acquiring an additional 1,340 shares during the period. 13.93% of the stock is owned by institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.